Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response (EDI-PIO)
Pilot Study of Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia With Deep Molecular Response - Evaluation of Pioglitazone in Treatment-free Remission (EDI-PIO)
Sponsor: University of Campinas, Brazil
Listed as NCT02852486, this PHASE2 trial focuses on Leukemia, Chronic Myeloid and remains completed. Sponsored by University of Campinas, Brazil, it has been updated 12 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Dec 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Campinas, Brazil
For direct contact, visit the study record on ClinicalTrials.gov .